

# Brisbane Cancer Conference

29–30 November 2018

Brisbane Convention and Exhibition Centre



## Conference Handbook



**PA** Research  
Foundation  
At the home of the world's first cancer vaccine



**brisbane diamantina  
health partners**

# CONFERENCE

# SPONSORS

## Platinum Sponsors



## Silver Sponsors



## Bronze Sponsors



## Pharma and Biotech Donations



## Institution donations



# WELCOME

brisbane diamantina  
health partners



Dear Colleagues,

Welcome to the 5th Brisbane Cancer Conference. With the establishment of the Brisbane Diamantina Health Partners as an NHMRC Advanced Health Research and Translation Centre, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant disease.

On Thursday 29th November, the meeting will start with Breast Cancer, Prostate Cancer, Immunology and Survivorship symposia running from 8am - 12pm in the morning. There will be a further satellite symposium at lunch-time followed by plenary lectures from 2 – 4pm and subsequently workshops running from 4:30 – 6:30pm. A conference dinner will be held on Thursday evening offering the opportunity to socialise with colleagues particularly from other institutions in the city and from Queensland. The all-day session on Friday 30th November will include plenary lectures followed by tumour-site specific workshops in the morning and afternoon. A key session will be lectures by cancer researchers that have contributed to global advances in our understanding of the epidemiology, molecular biology and treatment of malignant disease.

Based on registrations we are expecting in the region of 1,000 delegates to attend the meeting demonstrating the value of a truly multi-disciplinary annual Queensland Translational Cancer Conference in Brisbane. The conference is made possible through the support of the PA Research Foundation, Brisbane Diamantina Health Partners, our sponsors, the time and effort of the chairs who put the workshops together as well as Therese and the QUT Cancer and Ageing Research Program (CARP) team.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,

Professor Ken O'Byrne  
Consultant Medical Oncologist  
Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology



# CONFERENCE PROGRAM

DAY  
1

Thursday 29 November 2018

## Morning Symposia

7.00am	Arrival coffee and tea
<b>Breast cancer symposium (supported by Novartis)</b>	
<b>Boulevard Room</b> <span style="float: right;"><b>Chairs: Rik Thompson; Katharine Cuff, Georgia Chenevix Trench</b></span>	
<b>Genomics, prognostic factors and novel targets for therapy</b>	
8.00am	Germline events underlining breast cancer – Jonathan Beesley
8.20am	Somatic mutations in breast cancer – Peter Simpson
8.40am	Mammographic density in breast cancer – Honor Hugo
9.00am	Combining targeted therapies with immunotherapies – Fiona Simpson
9.20am	CDCA3 in breast cancer: prognostic factor and therapeutic target – Mark Adams
9.40am	CDK4/6: from the bench to the bedside – Nicole McCarthy
10-10.30am	Morning tea
<b>Translating science into precision medicine in breast cancer</b>	
10.30am	PI3K mutation targeted agents in breast cancer – Kathryn Middleton
10.50am	Targeting PARP in breast cancer – Vladimir Andelkovic
11.10am	Immunotherapy in breast cancer: recent advances and the future – Jasotha Sanmugarajah
11.30am	The SAFE trial: ‘ideal/highly supervised’ exercise vs that in the real world – Rosa Spence
11.50am	Discussion
<b>Prostate cancer (supported by Janssen)</b>	
<b>Boulevard Level, Room B1 and B2</b> <span style="float: right;"><b>Chairs: Colleen Nelson, Ian Vela</b></span>	
8.00am	Prostate cancer genomics in metastatic disease – Chris Hovens
8.20am	BRAC2 cohorts and relationship to intraductal prostate cancer – Damian Bolton
8.40am	PSA SNPs: clinical relevance – Jyotsna Batra
9.00am	Preclinical models of prostate cancer – Elizabeth Williams
9.20am	Liquid biopsies in prostate cancer – Matt Trau
9.40am	Neuropilin-1 a prognostic factor and target for therapy – Brett Hollier
10-10.30am	Morning tea
10.30am	Robotic vs standard surgery for prostate cancer – John Yaxley
11.00am	Translation of recent advances in the biology of prostate cancer into therapy: targeting the androgen receptor, homologous recombination and the immune response – Arun Azad
11.40am	Low dose testosterone for management of ADT toxicity – Handoo Rhee
11.50am	Discussion
<b>Immuno-oncology (supported by AstraZeneca)</b>	
<b>Boulevard Level, Room B3</b> <span style="float: right;"><b>Chairs: Riccardo Dolcetti, Rajiv Khanna</b></span>	
8.00am	Evolving understanding of immuno-biology in malignant disease – Mark Smyth
8.40am	Innate immunity and immunotherapy – Tobias Bald
9.00am	Clinical factors predicting benefit from immunotherapy – Rebecca Moor
9.20am	Biomarkers predicting efficacy of Immunotherapy – Wendy Cooper
9.40am	Radiotherapy enhances immunotherapy: fact or fiction – Ben Chua
10-10.30am	Morning tea
10.30am	Update on immunotherapy in the MoST study – David Thomas
10.50am	Recognising and managing immunotherapy toxicity – Kenneth O’Byrne
11.10am	Recent advances in cancer vaccines – Riccardo Dolcetti
11.30am	Adoptive T-cell therapies in oncology – Rajiv Khanna
<b>Survivorship (supported by Menarini)</b>	
<b>Boulevard Auditorium</b>	
<b>Title:</b> Queensland cancer survivorship collaborative concept development workshop	
<b>Faculty Members:</b> Liz Eakin, Jane Turner, Geoff Mitchell, Louisa Gordon, David Wyld, Lee Jones, Ray Chan	
8.00am	A two phase study to develop, implement and evaluate a pilot model of post-treatment specialist multidisciplinary survivorship care for adolescents and young adults living with cancer across Queensland – Lucy Holland
9.00am	AMBER: Addressing Modifiable Health Behaviours and Cancer Late-Effects in Children and Adolescents – Dr Natalie Bradford

# CONFERENCE PROGRAM

DAY  
1

Thursday 29 November 2018

## Morning Symposia continued

10-10.30am	Morning tea
10.30am	The psychosocial needs of younger female breast and gynaecological cancer survivors – Mingshuang Ding
11.00am	Retrospective-prospective cohort study of patients treated with chemotherapy and/or immunotherapy known to cause cardiac dysfunction – Penelope Stevens
11.30am	Discussion

12.20pm Roche Sponsored lunch

## Lunch-time Symposium

Lunch-time symposium (supported by Roche)	
Boulevard Auditorium	Chair: Kenneth O'Byrne
12.20pm	Targeted therapies in solid tumours: expanding opportunities – Chee Lee
<b>12.50pm</b>	<b>What have we learnt about immunotherapy this year?</b>
12.50pm	Tumor mutation burden and neoantigens – Nic Waddell
12.58pm	Breast cancer – Jasotha Sanmugarajah
1.06pm	Head and neck cancer – Brett Hughes
1.14pm	Genito-Urinary and Gynaecology – Jeff Goh
1.22pm	Lung Cancer – Kenneth O'Byrne
1.30pm	Panel discussion

## Afternoon Plenary Sessions

1.30pm Arrival refreshments

Plenary Thursday pm	
Boulevard Auditorium	
<b>Session 1</b>	<b>Chairs: Damian Topp, David Bunker</b>
2.00pm	Vision for Oncology Diagnostics in Queensland – Keith McNeill
2.20pm	Evolution of genomics into cancer care and research – Sunil Lakhani
2.40pm	Germline cancer risk tsunami; are we ready yet? – Aideen McInerney-Leo
<b>Session 2</b>	<b>Chairs: Janet Hardy, Leanne Stone</b>
3.00pm	The impact of novel therapies on the integration of palliative medicine and cancer care – Janet Hardy
3.30pm	Marijuana – the herbal medicine for everyone and everything? – Philip Goode
4.00pm	Tea and Coffee

## Afternoon Workshops

Imaging	
Arbour Level, Room A1	Co-ordinators: Paul Thomas, Pam Russell, Tom Lloyd
4.30pm	Potential applications of 7T MRI in cancer imaging – Markus Bath
4.50pm	Clinical experience of PET/MR in oncology – Philip Law
5.10pm	Imaging techniques for cancer models in mice – Brian Tse
5.30pm	Imaging of perineural spread in head and neck cancer – Jennifer Sommerville
5.50pm	Theranostics and prostate cancer – David Pattison
6.10pm	Breast MRI to predict treatment response to neoadjuvant chemotherapy – Gorane Santamaria

# CONFERENCE PROGRAM

DAY  
1

Thursday 29 November 2018

## Afternoon Workshops continued

Commercialisation	
Arbour Level, Room A2 <span style="float: right;">Moderator: Lyn Griffiths</span>	
4.30pm	<p><b>'Fire-side chat forum'</b>  <b>Taking your idea from the bench to the bedside</b></p> <ul style="list-style-type: none"> <li>• Cherrell Hirst, Chairperson, Factor Therapeutics</li> <li>• Peter Tapley, Pre-clinical Toxicology, TetraQ</li> <li>• Mark Reid, Clinical Regulations Consultant, Graythan Regulatory Services</li> <li>• Tim Evans, Biologics manufacturing in bacteria, Luina Bio</li> <li>• Colin Albert, CEO, Genomika: Genome Analysis for improved healthcare</li> <li>• Neil Finlayson, CEO, Vaccines, Admedus Immunotherapies</li> <li>• Anand Gautam, Head, External Science &amp; Innovation, Australia, NZ, &amp; Southeast Asia, Pfizer</li> </ul>
Clinical Trials	
Boulevard Level, Room B1 <span style="float: right;">Chairs: Adam Stoneley, Suzanne Elliott</span>	
4.30pm	<p>Queensland Health Tele-Trials Update – Roberta Lusa            Snapshot Profiles of Our Cancer Trials Units</p> <ul style="list-style-type: none"> <li>– Size, structure and staffing model of trials unit</li> <li>– Brief overview of clinical trial portfolio</li> <li>– Special features &amp; point of difference</li> </ul>
4.45pm	Gallipoli Medical Research Foundation – Suzanne Elliott
4.55pm	Princess Alexandra Hospital – Adrienne See
5.05pm	Pindara Hospital – Andrew McFadden
5.15pm	Sunshine Coast University Hospital – Helen Rodgers
5.25pm	University of Sunshine Coast – Lucas Litewka
5.35pm	Genesis Cancer Care – Vicki Sproule
5.45pm	Gold Coast University Hospital – Jacob Darch
5.55pm	Royal Brisbane & Women's Hospital – Robyn Western & Annette Cubitt
6.05pm	Mater Adult Hospital – Matthew Spitzer
6.15pm	Queensland Children's Hospital – Amy Smalley
6.25pm	Icon Cancer Centre – Adam Stoneley
Genomics	
Boulevard Level, Room B2 <span style="float: right;">Chair: John Pearson</span>	
4.30pm	Cancer Genomics, Australian Translational Genomics Centre – Matt Brown
4.50pm	The ICCOn project – Uwe Dressel & Aimee Davidson
5.10pm	Implementation project: Queensland Myeloid Genomics Program – Nicholas Weber
5.30pm	QGHA Genomic Information Management – Alejandro Metke
5.50pm	Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility – Emma Tudini
6.10pm	Discussion
Palliative Medicine	
Boulevard Level, Room B3 <span style="float: right;">Chairs: Janet Hardy, Leanne Stone</span>	
4.30pm	Talking death – Rebecca Olson
4.45pm	The factors associated with non-beneficial treatment at the end-of-life – Hannah Carter
5.00pm	Expenditure for investigations undertaken on patients approaching end-of-life – Gauri Gogna
5.15pm	Challenges in adolescent palliative care – Christine Mott
5.30pm	QT prolongation in palliative care patients – Jessica Cross
5.45pm	Holistic needs assessment of children admitted to Hummingbird house – Leigh Donovan
7.00pm 'til late	<b>Gala Dinner, Sky Room, Brisbane Convention and Exhibition Centre</b>

# CONFERENCE PROGRAM



Friday 30 November 2018

## Morning Plenary Session

7.00am	Arrival coffee and tea
<b>Plenary Friday am</b>	
<b>Boulevard Auditorium</b> <span style="float: right;"><b>Chairs: Allison Pettit, Michael Kimlin</b></span>	
8.00am	Whole genome sequencing from EBUS FNAs of lung cancer – David Fielding
8.20am	Novel liquid biopsies in cancer care – Matt Trau
8.40am	Management of oligo-metastatic disease: Radiotherapy perspective – David Pryor
9.00am	Oligometastatic disease: a surgical perspective – Paul Peters
9.20am	Supportive care needs: proof, provision and practice – Vanessa Beesley
9.40am	Big data – importance for out-patient nursing – Nina Simpson
10.00am	Tea and Coffee

## Morning Workshops

<b>Brain Tumours</b>	
<b>Arbour Level, Room A1</b> <span style="float: right;"><b>Chairs: Mark Pinkham, Catherine Bettington</b></span>	
10.30am	Comparative neuro-oncology network – Simon Puttick
10.40am	Speech and language outcomes in adults and children following treatment for primary brain tumours – Greig de Zubicaray
10.50am	Glioma heterogeneity – Seckin Akgul
11.00am	Powering and arming the immune system to combat Glioblastoma – Roberta Mazzieri
11.10am	Deregulation of differentiation in glioma – Jens Bunt
11.20am	Brain tumour theranostics – Kevin Lee
11.30am	Discussion
<b>Novel Immunotherapies</b>	
<b>Arbour Level, Room A2</b> <span style="float: right;"><b>Chairs: Rajiv Khanna, Riccardo Dolcetti</b></span>	
10.30am	Targeting the tumour microenvironment – Roberta Mazzieri
10.42am	Analysis for Tumour Mutation Burden in tumours – Paul Leo
11.54am	Lessons from HPV-driven carcinogenesis – Kelvin Tuong
11.06am	Cross-presenting dendritic cell therapy in solid tumours – Kelly-Anne Masterson
11.18am	Glioblastoma immunotherapy – Corey Smith
11.30am	Checkpoint Immunotherapy – Indrajit Das
11.42am	Early phase clinical trials in Queensland – Vladimir Andelkovic
11.50am	Discussion
<b>Thoracic Malignancies</b>	
<b>Boulevard Level, Room B1</b> <span style="float: right;"><b>Chairs: Brett Hughes, Simon Bowler, Henry Marshall</b></span>	
10.30am	Optimising Clinical Care and Research for the delivery of Precision Medicine in Thoracic Malignancies in Queensland <ul style="list-style-type: none"> <li>• Lung Cancer Institute concept – Kenneth O’Byrne</li> <li>• Tissue collection and biobanking – David Fielding</li> <li>• ‘Omics/bioinformatics – John Pearson</li> <li>• Liquid biopsies – Chamindie Punyadeera</li> <li>• DNA repair – Emma Bolderson</li> <li>• Screening &amp; Imaging – Henry Marshall</li> <li>• Clinical trials portfolio including targeted therapies and immunotherapy – Abishek Joshi</li> <li>• Surgery – TBC</li> <li>• Palliative medicine – James Stevenson</li> <li>• Survivorship – Ray Chan</li> </ul> <p><b>Panel members:</b> Matt Trau, Andreas Moeller, Rahul Ladwa</p>

# CONFERENCE PROGRAM

DAY  
2

Friday 30 November 2018

## Morning Workshops continued

Pharmacy	
<b>Boulevard Level, Room B2</b>	
<b>Chairs: Dan McKavanagh, Emily Wenta</b>	
10.30am	Developing a procurement guide for oncology and related pharmaceuticals – Michael Powell
10.45am	Scaling Cancer Pharmacy Education to Meet the Needs of an International Workforce – Courtney Oar
11.00am	Implementation of a Quality Assurance Framework for Oncology Pharmacy Practice within a National Pharmacy Network – Chris Giles
11.15am	Ramsay CHARM Rollout – A Pharmacist-Led Adventure in Managing Organisational & Systems Change – Jameson Fawns
11.30am	Activity based funding: funding the pharmacist – Christine Carrington
11.45am	Discussion
GU Malignancies	
<b>Boulevard Level, Room B3</b>	
<b>Chairs: Jeff Goh, Elizabeth Williams</b>	
Clinical and Translational research in GU malignancies in Queensland	
10.30am	Advances & trials in renal cell cancer care – Jeff Goh
10.40am	Bladder <ul style="list-style-type: none"> <li>– Overview of bladder cancer – Aneta Suder (5 mins)</li> <li>– Biomarkers for bladder cancer – Prashant Kumar (15 mins)</li> </ul>
11.10am	Prostate cancer <ul style="list-style-type: none"> <li>– Advances and trials in Prostate Cancer therapy – Jeff Goh (15 mins)</li> <li>– Theranostics in prostate cancer – Pam Russell &amp; Kevin Lee (15 mins)</li> <li>– Inhibiting resistance mechanisms in PTEN-deficient prostate cancer – David Waugh (15 mins)</li> </ul>
11.55am	Discussion: Future studies
Gynae-oncology	
<b>Boulevard Room</b>	
<b>Chairs: Lewis Perrin, John Hooper</b>	
10.30am	Evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer – Sinead Barry
10.44am	Pharmacological intervention opportunities for HPV related gynaecological cancers – Brian Gabrielli
10.58am	Harnessing the immune system for ovarian cancer treatment – Sherry Wu
11.12am	Bariatric surgery and endometrial cancer trial – Kate O'Hare
11.26am	Recent trials including potential of immune checkpoint therapies for gynaecological cancers – Jim Coward
11.40am	Clinical utility in ovarian cancer of HR defects in breast cancer – Nic Waddell
11.45am	Discussion
12.00pm	Tea and Coffee

## Lunch-time Plenary Session

Plenary Friday lunch-time	
<b>Boulevard Auditorium</b>	
<b>Chairs: Frank Gannon, Paul Clarke</b>	
12.30pm	Skin cancer screening – Peter Soyer
12.50pm	Advances in systemic therapy of head and neck cancer – Brett Hughes
1.10pm	Tumour mutation burden and cancer immunotherapy – Kenneth O'Byrne
1.30pm	Future care of rare tumours – David Thomas
2.00pm	Tea and Coffee



# CONFERENCE PROGRAM

DAY  
2

Friday 30 November 2018

## Afternoon Workshops

Small 3D Cancer Models	
<b>Arbour Level, Room A1</b>	
<b>Chairs: Laura Bray, Nathalie Bock</b>	
2.30pm	3D Models Coupled with Live Cell Imaging to Study Dynamic Melanoma Invasion – Robert Ju
2.43pm	Engineering a human bone metastatic microenvironment in vitro for therapy assessment – Nathalie Bock
2.56pm	Modelling chemo-resistance in non-small lung cancer utilising a novel 3D cell culture technology – Sarah-Louise Ryan
3.09pm	Assessment of cellular signalling in an organoid model of normal mammary gland development – Teneale Stewart
3.22pm	Making Organoids – Lessons Learned from Cardiac Organoid Bioengineering – James Hudson
3.35pm	Using ex vivo culture to assess patient therapy response – Tashbib Khan
3.48pm	A 3D model of osteoblastic stimulation by prostate cancer – Anthony Atack
Breast Cancer	
<b>Arbour Level, Room A2</b>	
<b>Chairs: Rik Thompson, Sunil Lakhani</b>	
Emerging themes and projects in Brisbane	
2.30pm	Radiation oncology trials – Nicola Lowrey
2.45pm	Q-IMPROvE – Amy McCart-Reed
3.00pm	CRISP-R: Applications in breast cancer – Sefi Rosenbluh
3.15pm	Epithelial Mesenchymal Transition – Andy Redfern
3.30pm	Consumer input into research – Leonie Young
3.45pm	A Humanized Mouse Model for Breast Cancer Study – Abbas Shafiee
Melanoma and Skin Cancer	
<b>Boulevard Level, Room B1</b>	
<b>Chairs: Mitchell Stark, Loredana Spoerri</b>	
2.30pm	Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma – Blake Ferguson
2.40pm	Development of a spider peptide as a therapeutic to treat metastatic melanoma – Sónia Henriques
2.50pm	Genomics and biological correlates of radiomics in melanoma – Lauren Aoude
3.00pm	Characterising the unique oncogenic signalling of uveal melanoma – Kelly Brooks
3.10pm	CHK1 inhibitor + low dose hydroxyurea effectively controls melanoma growth and triggers immunostimulatory signals without significant myelosuppression – Martina Proctor
3.20pm	Distinct roles for host and tumor intrinsic CD155 in tumor growth and metastasis – Indrajit Das
3.30pm	Microtubule-Dependent Mechanosensing in Cell Migration and Cancer Invasion – Sam Stehbens
3.40pm	Dissecting transcriptional drivers of melanoma plasticity: can we block melanomas escape route? – Aaron Smith
3.50pm	Functional analysis of MTAP haplotypes in melanoma risk – Rick Sturm
Head and Neck Cancer	
<b>Boulevard Level, Room B2</b>	
<b>Chairs Chris Perry</b>	
2.30pm	Overview of clinical trials in head and neck cancer in Queensland – Rahul Ladwa
2.40pm	Oral HPV infection, head and neck cancer and sexual behavior – Annika Antonnson
2.50pm	Introduction to Barcoding for HPV Oropharyngeal Cancer – Jazmina Gonzales Cruz
3.00pm	Pathos Trial and de-escalation of HPV Head and Neck Cancer Treatment – Liam Masterton
3.10pm	Circulating tumour cells in head and neck cancer – Arutha Kalusinghe
3.20pm	Adenoid Cystic Carcinoma in Queensland – Fiona Simpson
3.32pm	CXCR in head and Neck Cancer – Sarju Vasani
3.46pm	Discussion

# CONFERENCE PROGRAM

DAY  
2

Friday 30 November 2018

## Afternoon Workshops continued

GI Malignancies	
<b>Boulevard Level, Room B3</b>	
<b>Chairs: Chris Gillespie, Vikram Jain</b>	
2.30pm	The use of MRI as a prognostic indicator in rectal cancer – Kate MacLean
2.40pm	Biomarkers predicting pathological complete response in rectal cancer – Joseph Kong
2.50pm	Appendiceal tumours: lessons to be learnt from an audit of outcomes in Queensland – Hussain Al-Khdhur
3.00pm	Outcomes of pelvic exenteration in a centralized service – David Taylor
3.10pm	Studies in colorectal cancer at RBWH: Matt Burge – Circulating tumor DNA analysis informing adjuvant chemotherapy in stage III colon cancer: a multicenter phase II/III randomized controlled study (DYNAMIC-III) – Enhancing immunotherapy in colorectal cancer: an RBWH study
3.25pm	Regorefinib and aspirin, a phase I/II study – Rahul Ladwa
3.35pm	Theranostics for colorectal cancer – Tahleesa Cuda
3.45pm	Emerging role of SABR for liver cancer – David Pryor
3.55pm	Discussion
Survivorship	
<b>Boulevard Room</b>	
<b>Chairs: Ray Chan, David Wyld</b>	
Patient Reported Outcomes in Routine Care Queensland (Panel Discussion)	
2.30-4.00pm	What is the future of PRO in routine care? How can we synergise to make sure we get the biggest bang for our buck? <b>Panel:</b> Leanne Stone, Bena Cartmill, Melissa Eastgate, Natasha Roberts, Danica Cassio, Penny Webb, Daniel Mckavanagh and Natalie Bradford
4.00pm	Refreshment Break


## Evening Plenary Session

Plenary Friday evening – GATTACA	
<b>Boulevard Auditorium</b>	
<b>Chairs: Michael Cleary, Keith McNeill</b>	
4.15pm	Siemens AI program in oncology – Eric Imbert
4.40pm	Genomics and AI – Nicholas Therkelsen-Terry
5.05pm	Discussion
5.15pm	Wine and Cheese
6.00pm	Exit


# CONFERENCE FLOOR PLANS




**BRISBANE**  
convention  
& exhibition  
**CENTRE**



## Boulevard Level




## Arbour Level



# SPONSOR

# FLOOR PLAN



Roche	10
Astrazeneca	9
Bristol Myers Squibb	3
Boehringer-Ingelheim	4
Menarini	8
MSD	11
Pfizer	12
Amgen	1
Teva	2
Janssen	5

Novartis	6
Merck Serono	7
Agena Bioscience	13
Seqiris	14
Astellas	15
Mundipharma	16
Ferring	17
Ipsen	18
Servier	19

## Brisbane Cancer Conference

29–30 November 2018  
Brisbane Convention and Exhibition Centre



brisbane diamantina  
health partners